Recurrent Head And Neck Squamous Cell Carcinoma Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 65+ Leading Players Wheeling the Therapeutics Landscape

The recurrent head and neck squamous cell carcinoma clinical trial analysis report delivers important insights into ongoing research on 75+ pipeline recurrent head and neck squamous cell carcinoma drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

New York, USA, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Recurrent Head And Neck Squamous Cell Carcinoma Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 65+ Leading Players Wheeling the Therapeutics Landscape

The recurrent head and neck squamous cell carcinoma clinical trial analysis report delivers important insights into ongoing research on 75+ pipeline recurrent head and neck squamous cell carcinoma drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'Recurrent Head and Neck Squamous Cell Carcinoma Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for recurrent head and neck squamous cell carcinoma across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the recurrent head and neck squamous cell carcinoma domain.

Recurrent Head And Neck Squamous Cell Carcinoma Clinical Trial Analysis Summary

• DelveInsight’s recurrent head and neck squamous cell carcinoma pipeline report depicts a robust space with 65+ active players working to develop 75+ pipeline recurrent HNSCC drugs. 
• Key recurrent head and neck squamous cell carcinoma companies, such as Aveo Pharmaceuticals, Bicara Therapeutics, Sichuan Kelun-Biotech Biopharmaceutical, Glycyx Therapeutics, Sichuan Baili Pharmaceutical, GSK, Shanghai Hengrui Pharmaceutical, Lepu Biopharma, Shanghai Henlius Biotech, NATCO Pharma Ltd., BioNTech, Sutro Biopharma, Inc., Purple Biotech Ltd., Lyvgen Biopharma, Boehringer Ingelheim, Inhibrx Biosciences, Inc., Xilio Therapeutics, Neuvogen, PDS Biotech, Grey Wolf Therapeutics, Cellid Company, Nykode Therapeutics, Suzhou Junde Biotechnology Co., Ltd, Shanghai Henlius Biotech, and others, are evaluating new recurrent HNSCC drugs to improve the treatment landscape.
• Promising pipeline recurrent head and neck squamous cell carcinoma therapies, such as Ficlatuzumab, BCA101, SKB571, Axelopran, BL-B16D1, GSK5764227, SHR-A2102, MRG003, HLX43, NRC-2694, BNT113, STRO-004, NT219, LVGN6051, BI 770371, INBRX-106, XTX-601, NGEN-181, PDS0101, GRWD5769, BVAC-E6E7, VB10.16, TL117, HCB101, and others, are in different phases of recurrent HNSCC clinical trials.
• Approximately 4+ recurrent head and neck squamous cell carcinoma drugs are in the late stages of development.
• Notable MoAs in recurrent head and neck squamous cell carcinoma clinical trials include Hepatocyte growth factor inhibitors, Proto-oncogene protein c-met inhibitors, Epidermal growth factor inhibitors; Transforming growth factor beta inhibitors, EGFR antagonists; c-Met inhibitors, Opioid mu receptor antagonists, B7-H3-targeted Topoisomerase I inhibitor, Anti-nectin-4, Tissue Factor–targeted Topoisomerase inhibitor, and others.

Request a sample and discover the recent advances in recurrent head and neck squamous cell carcinoma treatment @ https://www.delveinsight.com/report-store/recurrent-head-and-neck-cancer-squamous-cell-carcinoma-pipeline-insight

What is Recurrent Head And Neck Squamous Cell Carcinoma?

Recurrent head and neck squamous cell carcinoma (HNSCC) refers to HNSCC that returns after initial treatment and a period of remission or disease control. Recurrence can develop at the original tumor site (local recurrence), in nearby lymph nodes (regional recurrence), or at distant sites such as the lungs (distant recurrence). It may occur months or years after treatment with surgery, radiation therapy, chemotherapy, immunotherapy, or combinations of these approaches. Recurrent HNSCC is particularly challenging to manage because treatment options may be limited by prior therapies, tumor resistance, and the patient’s overall condition, creating a significant unmet need for effective treatment strategies.

Find out more about treatment for recurrent HNSCC @ Recurrent Head And Neck Squamous Cell Carcinoma New Treatment

A snapshot of the Pipeline Recurrent Head And Neck Squamous Cell Carcinoma Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
Ficlatuzumab	Aveo Pharmaceuticals	III	Hepatocyte growth factor inhibitors; Proto-oncogene protein c-met inhibitors	IV infusion
BCA101	Bicara Therapeutics	II/III	Epidermal growth factor inhibitors; Transforming growth factor beta inhibitors	IV infusion
SKB571	Sichuan Kelun-Biotech Biopharmaceutical	II	EGFR antagonists; c-Met inhibitors	IV infusion
Axelopran	Glycyx Therapeutics	II	Opioid mu receptor antagonists	Oral
GSK5764227	GSK	II	B7-H3-targeted Topoisomerase I inhibitor	IV infusion
SHR-A2102	Shanghai Hengrui Pharmaceutical	I/II	Anti-nectin-4	IV
STRO-004	Sutro Biopharma, Inc.	I	Tissue Factor–targeted Topoisomerase inhibitor	IV
BL-B16D1	Sichuan Baili Pharmaceutical	I	Undefined mechanism	IV

Learn more about the recurrent HNSCC research @ Recurrent Head And Neck Squamous Cell Carcinoma Clinical Trials 

As per Arunima Dabral, Assistant Project Manager of Consulting & Competitive Intelligence at DelveInsight, the recurrent/metastatic HNSCC pipeline is increasingly focused on addressing the substantial unmet need in patients who progress after standard chemotherapy and immune checkpoint inhibition, with development shifting toward novel targeted modalities, antibody–drug conjugates, bispecific antibodies, and next-generation immunotherapeutic approaches. Increasing emphasis on biomarker-driven patient selection, combination strategies, and therapies capable of generating durable responses in heavily pretreated populations is expected to shape the evolving pipeline, while diversification beyond conventional chemotherapy and checkpoint inhibition may provide additional treatment options across different lines of therapy.

Recent Developments in Recurrent Head And Neck Squamous Cell Carcinoma Treatment Space

• In September 2026, Pyxis Oncology announced positive updated Phase I data for micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). MICVO demonstrated a 36% confirmed objective response rate and 94% disease control rate, with a median progression-free survival of 6.2 months. The company plans to initiate the Phase III Headliner trial in the second-line and beyond R/M HNSCC setting in mid-2027.
• In July 2026, Johnson & Johnson announced that the U.S. FDA had granted Priority Review to the supplemental Biologics License Application for subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO™) for adults with recurrent or metastatic HNSCC. The application was supported by data showing a 42% overall response rate, with one-third of responders achieving a complete response, in previously treated patients.
• In May 2026, Johnson & Johnson announced pivotal data from the Phase Ib/II OrigAMI-4 study evaluating subcutaneous amivantamab and hyaluronidase-lpuj in patients with recurrent or metastatic HNSCC previously treated with immunotherapy and chemotherapy. The company reported strong and durable responses and announced submission of a supplemental Biologics License Application to the US FDA for this indication.
• In May 2026, Rakuten Medical announced new clinical data from the global Phase III ASP-1929-301 study evaluating ASP-1929 photoimmunotherapy as monotherapy in patients with locoregional recurrent HNSCC who had failed or progressed after at least two prior lines of therapy and were not eligible for surgery or radiation. The company reported results from 135 randomized patients, including efficacy, safety, and quality-of-life outcomes.
• In April 2026, Rakuten Medical announced that results from its global Phase III ASP-1929-301 study would be presented at the 2026 ASCO Annual Meeting. The study evaluates ASP-1929 photoimmunotherapy in patients with locoregional recurrent HNSCC and represents a Phase III evaluation of the treatment in this setting.
• In February 2026, Rakuten Medical announced that the first patient in Ukraine had been treated in its global Phase III ASP-1929-381 trial evaluating ASP-1929 photoimmunotherapy in combination with pembrolizumab as first-line treatment for patients with recurrent HNSCC. More than 30 clinical sites across the United States, Taiwan, Japan, and Ukraine were actively recruiting patients.
• In February 2026, Bicara Therapeutics reported Phase Ib expansion-cohort data for ficerafusp alfa in combination with pembrolizumab in first-line HPV-negative recurrent/metastatic HNSCC. The company reported rapid, deep, and durable responses and stated that the data supported development of a less-frequent dosing regimen for ficerafusp alfa.
• In February 2026, Johnson & Johnson announced that the U.S. FDA had granted Breakthrough Therapy Designation to subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO™) for adults with recurrent or metastatic, HPV-unrelated HNSCC following progression on or after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.

Scope of the Recurrent Head And Neck Squamous Cell Carcinoma Pipeline Report 

• Coverage: Global 
• Recurrent Head And Neck Squamous Cell Carcinoma Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Recurrent Head And Neck Squamous Cell Carcinoma Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Recurrent Head And Neck Squamous Cell Carcinoma Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Recurrent Head And Neck Squamous Cell Carcinoma Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Recurrent Head And Neck Squamous Cell Carcinoma Therapeutics Assessment By Mechanism of Action: Hepatocyte growth factor inhibitors, Proto-oncogene protein c-met inhibitors, Antibody-dependent cell cytotoxicity, Epidermal growth factor inhibitors, T lymphocyte stimulants; Transforming growth factor beta inhibitors, Dual-targeted antibody-drug conjugate (bispecific ADC), Opioid mu receptor antagonists, DNA topoisomerase inhibitors, and others
• Key Recurrent Head And Neck Squamous Cell Carcinoma Companies: Aveo Pharmaceuticals, Bicara Therapeutics, Sichuan Kelun-Biotech Biopharmaceutical, Glycyx Therapeutics, Sichuan Baili Pharmaceutical, GSK, Shanghai Hengrui Pharmaceutical, Lepu Biopharma, Shanghai Henlius Biotech, NATCO Pharma Ltd., BioNTech, Sutro Biopharma, Inc., Purple Biotech Ltd., Lyvgen Biopharma, Boehringer Ingelheim, Inhibrx Biosciences, Inc., Xilio Therapeutics, Neuvogen, PDS Biotech, Grey Wolf Therapeutics, and others.
• Key Recurrent Head And Neck Squamous Cell Carcinoma Pipeline Therapies: Ficlatuzumab, BCA101, SKB571, Axelopran, BL-B16D1, GSK5764227, SHR-A2102, MRG003, HLX43, NRC-2694, BNT113, STRO-004, NT219, LVGN6051, BI 770371, INBRX-106, XTX-601, NGEN-181, PDS0101, GRWD5769, and others.

Dive deep into rich insights for recurrent HNSCC cure, visit @ Recurrent Head And Neck Squamous Cell Carcinoma News

Table of Contents

1.	Recurrent Head And Neck Squamous Cell Carcinoma Pipeline Report Introduction
2.	Recurrent Head And Neck Squamous Cell Carcinoma Pipeline Report Executive Summary
3.	Recurrent Head And Neck Squamous Cell Carcinoma Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Recurrent Head And Neck Squamous Cell Carcinoma Clinical Trial Therapeutics
6.	Recurrent Head And Neck Squamous Cell Carcinoma Pipeline: Late-Stage Products (Pre-registration)
7.	Recurrent Head And Neck Squamous Cell Carcinoma Pipeline: Late-Stage Products (Phase III)
8.	Recurrent Head And Neck Squamous Cell Carcinoma Pipeline: Mid-Stage Products (Phase II)
9.	Recurrent Head And Neck Squamous Cell Carcinoma Pipeline: Early-Stage Products (Phase I)
10.	Recurrent Head And Neck Squamous Cell Carcinoma Pipeline Therapeutics Assessment
11.	Inactive Products in the Recurrent Head And Neck Squamous Cell Carcinoma Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Recurrent Head And Neck Squamous Cell Carcinoma Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the recurrent HNSCC clinical trials, reach out @ Recurrent Head And Neck Squamous Cell Carcinoma Medication

Related Reports

Recurrent Head And Neck Squamous Cell Carcinoma Market

Recurrent Head And Neck Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key recurrent HNSCC companies, including Glycyx Therapeutics, Sichuan Baili Pharmaceutical, GSK, Shanghai Hengrui Pharmaceutical, Lepu Biopharma, Shanghai Henlius Biotech, NATCO Pharma Ltd., BioNTech, Sutro Biopharma, Inc., Purple Biotech Ltd., Lyvgen Biopharma, Boehringer Ingelheim, Inhibrx Biosciences, Inc., and others.

Head And Neck Squamous Cell Carcinoma Market

Head And Neck Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HNSCC companies, including Johnson & Johnson, BioNTech, Cue Biopharma, Genmab, Immutep, ISA Pharmaceuticals, PDS Biotechnology, Nykode Therapeutics, Inovio Pharmaceuticals, and others.

HPV16+ Head and Neck Squamous Cell Carcinoma Market

HPV16+ Head and Neck Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key HPV16+ HNSCC companies including Bristol Myers Squibb, Merck, Merus, Exelixis, ISA Pharmaceuticals, Regeneron Pharmaceuticals, PDS Biotechnology, BioNTech, Cue Biopharma, Immutep, Iovance Biotherapeutics, Inovio Pharmaceuticals, MedImmune, Nykode Therapeutics, RAPT Therapeutics, and others.

HPV16+ Cancers Market

HPV16+ Cancers Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HPV16+ cancers companies, including GlaxoSmithKline, PDS Biotechnology, Merck, Cue Biopharma, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Vaccibody AS, Transgene, Innovio Pharma, Hookipa Pharma, Roche Pharma AG, Invectys, BioNTech, Advaxis, Inc., Precigen, and others.

Human Papillomavirus Market

Human Papillomavirus Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HPV companies, including Inovio Pharmaceuticals, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Merck, Pattern Pharma, Nykode, Vaccibody A/S, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679